Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
21.2.2023 17:11:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano®, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
Compared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltrating tumors and crossing blood-brain barriers. Additionally, nanobodies generally have longer CDR3 regions which enables them to recognize hidden epitopes better. Due to their simpler structure, nanobodies are more stable and easier to produce and engineer, making them ideal building blocks for complex modalities such as cell therapy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC).
After several years of endeavor, Biocytogen successfully engineered the RenNano mouse from its fully human antibody mouse, RenMab™. RenNano mouse possesses full human heavy chain variable regions and can produce heavy-chain-only antibodies (HCAbs). The variable regions of HCAbs, i.e., nanobodies, do not require in vitro humanization to develop drugs. Our research has shown that RenNano mouse can generate robust immune responses after immunizations by different antigens. HCAbs generated from the RenNano mouse have highly diverse CDR3 sequences and can recognize many epitopes with nM-level high affinities. In vitro and in vivo experiments have shown that RenNano-derived antibodies have favorable biological functions.
Based on RenNano’s excellent ability to discover fully human nanobodies, Biocytogen has launched the “Nano 100 Project”. The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases. Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale nanobody development abilities with collaborators’ expertise in nanobody-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.
“We believe that with the ability to rapidly develop fully human nanobodies against selected targets, the ‘Nano 100 Project’ will provide our global partners with more diverse and better nanobody building blocks to accelerate the development of novel drugs,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Meanwhile, it is also an important supplement to Biocytogen’s Project Integrum.”
About RenNano®
Biocytogen's proprietary fully human nanobody generating mouse, RenNano, is one of the most comprehensive fully human antibody platforms in the world. Nanobody sequences generated from RenNano mice have the highest possible diversity and do not require antibody humanization, which saves time and cost and reduces the risk of failure during later stages of drug development. Additionally, compared to natural HCAb-producing species like camelids, mice are easier to breed and immunize, making them suitable for developing HCAbs on a large scale.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005554/en/
Contact information
Biocytogen
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Circle Expands Global Payments Infrastructure with Agreement to Acquire Singapore-Based Cross-Border Payments Platform, Tazapay8.9.2026 13:05:00 EEST | Press release
Circle Internet Group, Inc. (NYSE: CRCL), the global financial technology firm and issuer of USDC today announced it has signed a definitive agreement to acquire Tazapay, a Singapore-headquartered B2B cross-border payments infrastructure company focused on serving payment service providers and financial institutions. The deal is expected to close in 2027, subject to customary closing conditions and receipt of regulatory approvals, including approval from the Monetary Authority of Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908409825/en/ “Stablecoin settlement is becoming core infrastructure in the global economy, and combining USDC with Tazapay’s world-class banking relationships, local payout rails, and institutional customer base will accelerate worldwide USDC adoption,” said Jeremy Allaire, Co-Founder, CEO, and Chairman at Circle. “Tazapay has been a design partner for Circle Payments Network since 2025 a
Every Entrepreneur Needs Someone to Call: Lenovo and Eva Longoria Open a New Line of Support for Entrepreneurs with “Call Eva”8.9.2026 13:00:00 EEST | Press release
Lenovo today announced Call Eva, a new initiative from Lenovo’s global Backing Every Business program that gives entrepreneurs a direct line to call Eva Longoria, Lenovo’s global ambassador, for insights on business growth, leadership and entrepreneurship. Entrepreneurs can now call and leave a voice note with their biggest business questions. Select callers may then be contacted and offered the opportunity to speak with Eva, live on September 16. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908095710/en/ Running a business can feel lonely. The decisions are constant, the challenges are personal and, too often, entrepreneurs are left asking the same question: Who can I call who actually understands what I’m going through? The concept of Call Eva is simple: every entrepreneur needs someone they can call. As a business owner herself, Longoria understands what it means to build, lead and take risks. Beyond her work as an a
57% of Brands Can't Prove ROI on Sports Fan Engagement Despite Rising Investment8.9.2026 12:30:00 EEST | Press release
Research commissioned by Infobip, the global AI-first cloud communications platform celebrating 20 years, shows brands are significantly increasing investment in sports fan engagement even as many struggle to prove business impact. The global study of 500 marketing and digital leaders across industries, including retail, financial services, telecoms, travel, and food & beverage in 11 markets found that brands currently allocate an average of 13% of annual marketing budgets to sports-related activations, and nearly 73% expect investment to increase over the next 12 months. Yet while live sports moments generate the highest levels of fan engagement, nearly half (47%) of organizations admit they struggle to deliver real-time engagement during live events, and more than half (57%) say it is difficult to prove the ROI of their sports marketing investments. Ben Lewis, VP Marketing and Growth at Infobip, said: “Half of brands can't prove the ROI of their sports marketing – that's not a measur
Red Sea Global Unveils Nammos Resort AMAALA, Introducing Nammos’ First Resort Hotel Globally8.9.2026 11:59:00 EEST | Press release
Red Sea Global (RSG), the regenerative tourism developer, today announced the opening of Nammos Resort AMAALA, marking the launch of Nammos’ first resort hotel globally and a significant addition to AMAALA’s growing lifestyle and hospitality offering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908621917/en/ A marvellous view of the night sky from inside the resort hotel Set along the shores of Triple Bay with sweeping views across the Red Sea and Dumega Bay and designed around Nammos’ philosophy of Endless Joy, Nammos Resort AMAALA introduces the brand’s distinctive blend of Mediterranean sophistication and vibrant social energy to one of the world’s most comprehensive wellness destinations. “Nammos Resort AMAALA strengthens the diversity of experiences available across the destination bringing the unmistakable energy and spirit of Mykonos to the Saudi Red Sea coast. As AMAALA continues to expand with each new opening
Icon Solutions and MongoDB Benchmark Shows IPF Processing 6,000 Payments per Second with Zero Data Loss Under Failure8.9.2026 11:54:00 EEST | Press release
Icon Solutions and MongoDB today published the results of a joint benchmark showing that the Icon Payments Framework (IPF), running on MongoDB Atlas, processed 6,000 end-to-end payment transactions per second (around 430,000 database operations per second) with a mean end-to-end latency of 0.51 seconds, and recovered from both application and database node failures with zero data loss. Account-to-account payment volumes are moving rapidly onto instant rails. Traffic is migrating from net-settlement schemes to instant schemes, and direct debit volumes are expected to partially move to request-to-pay with settlement through instant schemes. For banks, that means sharper traffic peaks, a growing share of payments bound to scheme SLAs of a few seconds, and no tolerance for downtime. Sustaining several thousand payments per second while maintaining resilience, availability and low latency is routinely underestimated by institutions that self-build, and retro-fitting legacy platforms for alw
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom